Tyra Biosciences, Inc. Common Stock (TYRA) Stock Price
TYRAStock
$18.52+24.80%52W
Market Cap$1.27B
P/E—
PEG Ratio—
Div yield—
Beta0.66
TYRA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-57.40%
Price vs S&P 500 (4W)-26.47%
VGM Score47.23
TYRA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.64 | -$0.69 | -7.02%(-$0.05) | |
| Q1 2026 | -$0.59 | -$0.64 | -8.60%(-$0.05) | |
| Q4 2025 | -$0.53 | -$0.57 | -8.50%(-$0.04) | |
| Q3 2025 | -$0.51 | -$0.50 | +1.96%(+$0.01) | |
| Q2 2025 | -$0.51 | -$0.47 | +7.66%(+$0.04) |
TYRA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.33
4.32
4.32
4.32
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
TYRATyra Biosciences, Inc. Common Stock | — | — | C | — | — | — | — | $18.52 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Tyra Biosciences, Inc. Common Stock
Tyra Biosciences is a clinical-stage biotechnology company developing precision medicines targeting FGFR (Fibroblast Growth Factor Receptor) biology through its proprietary SNAP platform, which enables rapid drug discovery with optimized potency, selectivity, and safety profiles. The pipeline includes three clinical-stage small molecules (TYRA-300, TYRA-200, TYRA-430) designed to overcome the toxicity and resistance liabilities of first-generation FGFR inhibitors.